NCT02030275

A Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery in Healthy Adults

A Multi-Center, Prospective, Randomized, Double-Blind, Within-Subject Controlled, Phase 2a Study to Evaluate the Effectiveness and Safety of RXI 109 on the Outcome of Scar Revision Surgery on Transverse Hypertrophic Scars on the Lower Abdomen Resulting From Previous Surgeries in Healthy Adults

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: RXi Pharmaceuticals, Corp. · Industry
• Sex: All
• Age: 21 Years – 55 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to determine the effectiveness of RXI-109 in reducing the recurrence of hypertrophic scar formation following elective revision of a pre-existing hypertrophic abdominal scar.

Conditions

• Hypertrophic Scar

Interventions

Type	Name	Description
DRUG	RXI-109	surgery.
DRUG	Placebo	surgery.

Timeline

• Start date: 2013-11-01
• Primary completion: 2016-06-01
• Completion: 2016-06-01
• First posted: 2014-01-08
• Last updated: 2016-06-21

Locations

5 sites across 2 countries: United States, Honduras